Zotiraciclib for recurrent brain tumors with IDH mutations
Part of Brain & nervous system, Cancer clinical trials.
This early-phase study tests zotiraciclib in people with recurring diffuse gliomas (brain tumors) that have an IDH1 or IDH2 mutation. It may help slow the tumor or shrink it by targeting a specific change in tumor biology.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your diagnosis must be a diffuse glioma (WHO grade 2 to 4) confirmed by a lab
- Your tumor must have an IDH1 or IDH2 mutation (from a specific test or prior record)
- Your cancer must be back after prior treatment (like radiation, chemotherapy, or vorasidenib)
- You must be age 15 or older and able to do daily activities reasonably well (Karnofsky score over 70)
- You must be well enough for treatment based on blood counts, liver/kidney tests, and heart rhythm test (ECG)
- You must have no too-recent cancer relapses for Phase II, and you must not have had certain recent treatments or procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding all-trans retinoic acid (ATRA) to an anti–PD-1 immune therapy can slow recurrent or worsening IDH-mutant glioma. It may help by boosting the immune system’s attack on the tumor.
This trial tests a combination of two oral medications (vorasidenib and lomustine) for people whose brain tumor (glioma) has come back and has an IDH1 or IDH2 mutation. The goal is to see if this combination is safe and effective in halting or slowing tumor growth.
This Phase 2 study tests ribociclib with either everolimus or temozolomide, depending on the specific brain tumor type. It may help slow tumor growth in children and young adults whose tumor has specific genetic changes and who have had recent standard radiation therapy.
This trial tests a combination of two drugs (D2C7-IT and 2141-V11) given directly into the brain after surgery for people with recurrent glioblastoma. The goal is to see if this treatment is safe and can help control the tumor.
This trial tests a combination of two drugs—ivoximab (a new immunotherapy) and temozolomide (chemotherapy)—to treat gliomas (brain tumors) that have come back or stopped responding to prior treatment. The goal is to see if this combination is safe and effective.
This study tests an experimental drug called TQB3454 in people with advanced solid tumors, including brain tumors (gliomas) and bile duct cancer. The drug targets a specific gene change (IDH1) that may help control tumor growth. Participation may offer a new treatment option when standard treatments have stopped working.
Hear when a new Brain Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.